Phospholipid transfer protein, an emerging cardiometabolic risk marker: Is it time to intervene?

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 38-41

  Dullaart, R P F ^a   van Tol, A ^a,b   Dallinga Thie, G M ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CVD risk; PLTP

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID TRANSFER PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN METABOLISM; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN SECRETION; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 84876803611     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.043     Document Type: Note

References (37)

1. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002, 13:135-139.
2. Dallinga-Thie G.M., Dullaart R.P.F., van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007, 18:251-257.
3. Kappelle P.J.W.H., van Tol A., Wolffenbuttel B.H., Dullaart R.P.F. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther 2011, 29:e89-e99.
4. Kappelle P.J.W.H., Perton F., Hillege H.L., Dallinga-Thie G.M., Dullaart R.P.F. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011, 217:249-252.
5. Vergeer M., Dallinga-Thie G.M., Dullaart R.P.F., van Tol A. Evaluation of phospholipid transfer protein as a therapeutic target. Future Lipidol 2008, 3:327-335.
6. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Res 2009, 10:403-411.
7. Lagrost L. Plasma phospholipid transfer protein: a multifaceted protein with a key role in the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Hepatology 2012, 56:415-418.
8. Albers J.J., Vuletic S., Cheung M.C. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim Biophys Acta 2012, 1821:345-357.
9. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001, 7:847-852.
10. Yazdanyar A., Jiang X.C. Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice. Hepatology 2012, 56:576-584.
11. Desrumaux C., Deckert V., Lemaire-Ewing S., et al. Plasma phospholipid transfer protein deficiency in mice is associated with a reduced thrombotic response to acute intravascular oxidative stress. Arterioscler Thromb Vasc Biol 2010, 30:2452-2457.
12. Moerland M., Samyn H., van Gent T., et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1277-1282.
13. Masson D., Deckert V., Gauthier T., et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. Arterioscler Thromb Vasc Biol 2011 Apr, 31:766-774.
14. Vikstedt R., Ye D., Metso J., et al. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 2007, 27:578-586.
15. Ogier N., Klein A., Deckert V., et al. Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Arterioscler Thromb Vasc Biol 2007, 27:2407-2412.
16. van Haperen R., Samyn H., Moerland M., et al. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One 2008, 3:e2255.
17. Riemens S., van Tol A., Sluiter W., Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998, 140:71-79.
18. Desrumaux C., Athias A., Bessède G., et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999, 19:266-275.
19. Dullaart R.P.F., de Vries R., Dallinga-Thie G.M., Sluiter W.J., van Tol A. Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin Endocrinol (Oxf) 2008, 68:375-381.
20. de Vries R., Kappelle P.J., Dallinga-Thie G.M., Dullaart R.P.F. Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects. Atherosclerosis 2011, 217:253-259.
21. Dullaart R.P.F., Vergeer M., de Vries R., Kappelle P.J., Dallinga-Thie G.M. Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity. J Intern Med 2012, 271:490-498.
22. Colhoun H.M., Scheek L.M., Rubens M.B., et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001, 50:652-659.
23. Huuskonen J., Ekstrom M., Tahvanainen E., et al. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000, 151:451-461.
24. Dullaart R.P.F., De Vries R., Scheek L., et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004, 64:205-215.
25. Vergeer M., Boekholdt S.M., Sandhu, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
26. Jarvik G.P., Rajagopalan R., Rosenthal E.A., et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res 2010, 51:983-990.
27. Robins S.J., Brocia R.W., Massaro J.M., Vasan R.S. Plasma lipid transfer proteins and cardiovascular disease: the Framingham Heart Study. Atherosclerosis 2013, 228:230-236.
28. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23:1857-1862.
29. de Vries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H., van Tol A., Dullaart R.P.F. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
30. Schlitt A., Blankenberg S., Bickel C., et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009, 50:723-729.
31. Chen X., Sun A., Mansoor A., et al. Plasma PLTP activity is inversely associated with HDL-C levels. Nutr Metab 2009, 6:49.
32. Yatsuya H., Tamakoshi K., Hattori H., et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J 2004, 68:11-16.
33. Rühling K., Lang A., Richard F., et al. Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. Metabolism 1999, 48:1361-1366.
34. Schgoer W., Mueller T., Jauhiainen M., et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008, 196:219-226.
35. Dallinga-Thie G.M., van Tol A., Dullaart R.P.F., Diabetes Atorvastatin lipid intervention (DALI) study group Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein. Biochim Biophys Acta 2009, 1791:714-718.
36. Luo Y., Shelly L., Sand T., et al. Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. J Pharmacol Exp Ther 2010, 332:1100-1106.
37. Luo Y., Shelly L., Sand T., Chang G., Jiang X.C. Identification and characterization of dual inhibitors for phospholipid transfer protein and microsomal triglyceride transfer protein. J Pharmacol Exp Ther 2010, 335:653-658.